Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Unicycive Therapeutics faces a class action securities fraud lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The company's stock fell 39.1% following the announcement. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.